Conditioned place preference induced by licit drugs: establishment, extinction, and reinstatement. 2008

Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
National Institute on Drug Dependence, Peking University, Beijing, China. linlu@bjmu.edu.cn

The conditioned place preference (CPP) model has been widely used to evaluate the rewarding effects of abused drugs, and recently, the extinction and reinstatement phases of this paradigm have been used to assess relapse to drug seeking. The vast majority of studies have focused on CPP induced by illicit drugs, such as psychostimulants and opioids. Although legal psychoactive drugs, such as ethanol, nicotine, and caffeine, are more widely used than illegal drugs, the establishment, extinction, and reinstatement of CPP produced by these licit drugs are less well understood. The present review discusses the extant research on CPP induced by legal drugs. We first describe the CPP model and discuss the behavioral procedures used to induce CPP for ethanol, nicotine, and caffeine. We then summarize the neuronal substrates that underlie CPP induced by these drugs from a genetic perspective. Finally, we draw on findings from pharmacological studies and discuss the neurotransmitters and neurohormones underlying CPP produced by ethanol, nicotine, and caffeine.

UI MeSH Term Description Entries
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
December 2023, Addiction biology,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
October 2000, Behavioural brain research,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
January 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
September 2009, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
October 2011, Neuroscience letters,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
August 2019, Behavioural pharmacology,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
January 2014, Psychopharmacology,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
January 2014, Psychopharmacology,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
January 2019, Brain stimulation,
Yu Liu, and Bernard Le Foll, and Yanli Liu, and Xi Wang, and Lin Lu
June 2006, Behavioural pharmacology,
Copied contents to your clipboard!